The development of RIC and various other methods that select RBPs crosslinked to RNA has been essential for expanding the compendium of RBPs. These methodologies have led to the identification of several candidate RBPs that will be examined in depth in this proposal, including metabolic enzymes in cancer cells, or p62/SQSTM1 after SARS-CoV-2 infection from the Castello group, or in T cells from the Wolkers group.
